SecBot SecBot
6-K ·Filed Apr 27, 2026

PPBT

PURPLE BIOTECH LTD.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001213900-26-047709
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor for upcoming IND filings or clinical trial initiation announcements for IM1240, which would be the next major value inflection point. This data strengthens the platform's differentiation and could attract biotech partners or investors focused on next-gen immunotherapies, particularly in resistant solid tumors.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.59
T+0 close · Apr 27, 2026 · via day close
Latest settled
−71.02%
T+60 · $1.33
Vs SPY
−75.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $4.59entry
  2. T+1 · 7mo ago −1.02%α −0.54% · $4.54
  3. T+5 · 7mo ago −8.06%α −8.46% · $4.22
  4. T+20 · 6mo ago −36.82%α −41.78% · $2.90
  5. T+60 · 4mo ago −71.02%α −75.80% · $1.33

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech announced new preclinical data showing that its tri-specific antibody IM1240 demonstrated potent anti-tumor activity across all seven tested patient-derived tumor samples, including treatment-resistant cancers. The data highlight the critical role of the NKG2A arm in enhancing anti-tumor response and inducing tertiary lymphoid structures associated with improved clinical outcomes.

Key Facts

  • New preclinical data show IM1240 induced anti-tumor responses in all 7 patient-derived tumor samples tested, including PD-1-resistant head and neck cancer and bladder cancer.
  • The NKG2A arm of IM1240 was shown to significantly enhance anti-tumor activity and improve therapeutic index, with loss of efficacy observed when this arm was mutated.
  • IM1240 induced mature tertiary lymphoid structures (TLS) in NSCLC biopsies, biomarkers linked to strong anti-tumor immunity and better prognosis.
  • IM1240 is part of the CAPTN-3 platform, a conditionally activated, masked tri-specific antibody designed to target tumors while minimizing systemic toxicity.
  • The company remains in clinical-stage development with no commercial products yet; these results support progression toward clinical trials.

Financial Impact

No immediate financial impact, but de-risked development pathway for IM1240 increases likelihood of partnerships or funding. Market cap remains small at $4M, suggesting high optionality value on clinical advancement.

R&D pipeline valuepartnership potentialinvestor sentiment

Risk Factors

  • Preclinical data may not translate to human clinical efficacy.
  • Company has limited financial resources and no near-term revenue; dependent on financing or partnerships.
  • Highly competitive immuno-oncology landscape with multiple T-cell engagers in development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-047709
Document: ea028779601ex99-1.htm0001213900-26-047709
Document: 0001213900-26-047709-index-headers.html0001213900-26-047709
Document: 0001213900-26-047709-index.html0001213900-26-047709
Document: 0001213900-26-047709.txt0001213900-26-047709

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026